Key Takeaways HIMS and Doximity reflect two distinct digital health models across consumer and provider platforms.DOCS benefits from a scaled physician network and diversified tools across marketing, hiring and workflows.HIMS drives growth via subscriptions, telehealth integration and expansion into broader care categories.Digital healthcare continues to evolve across both direct-to-consumer and professional-focused platforms, with Hims & Hers Health, Inc. (HIMS) and Doximity, Inc. (DOCS) representing two d ...

Doximity, Inc. (NYSE:DOCS) is among the 10 Best New AI Stocks to Buy. On March 18, Freedom Capital analyst Gene Mannheimer initiated coverage on Doximity, Inc. (NYSE:DOCS) with a Buy rating and a $31 price target, highlighting the company’s strong network effects, scalable business model, and above-average growth potential. The analyst emphasized that recent share price weakness presents an attractive entry point, suggesting that the market may be underestimating the company’s long-term earnings power. ...

Core Viewpoint - Freedom Capital Markets initiated coverage on Doximity Inc. with a Buy rating and a $31 price target, emphasizing the company's strong growth potential and network effects [1] Group 1: Company Overview - Doximity is described as a comprehensive digital ecosystem for healthcare professionals, facilitating collaboration, content access, clinical workflow management, and medical practice [2] - The platform exhibits high user engagement and strong network effects, which are expected to drive above-average growth and significant operating leverage as the business scales [2] Group 2: Market Position and Challenges - The firm acknowledged competitive pressures from a fragmented landscape of specialized point solutions that offer "best-of-breed" functionality [3] - Despite these challenges, the recent decline in Doximity's stock price is viewed as an attractive entry point, with potential upside of approximately 25% [3] - Risks related to pharmaceutical advertising spending trends and the emergence of a notable competitor were noted, but the risk-reward profile is considered favorable [3]

Core Insights - The Doximity report reveals that 94% of physicians are currently using or interested in using AI, but 71% express concerns regarding its accuracy and reliability [1][2]. Group 1: AI Adoption and Usage - AI adoption among physicians has significantly increased, with usage rising from 47% in April 2025 to 63% in January 2026, marking a 16-point increase [3]. - Neurologists have the highest AI adoption rate at 64%, followed by gastroenterologists at 61% and internists at 60% [3]. - One-third (37%) of physicians reported using AI at least daily, while 54% of all surveyed physicians indicated they use AI in their practice [3]. Group 2: Benefits of AI - AI is perceived to help reduce administrative burdens, with 90% of physicians believing it can decrease "pajama time," the after-hours work contributing to burnout [6]. - Two-thirds (69%) of AI users reported improvements in patient care and outcomes, and 75% noted a reduction in administrative workload and an increase in job satisfaction [6]. Group 3: Specific AI Applications - Voice-based documentation, including ambient listening and AI scribes, increased from 20% to 29% among physicians over the study periods [3]. - Literature search emerged as the most common AI use case, rising from 22% in April 2025 to 35% in January 2026 [3].

Core Viewpoint - Investors are selling off software stocks due to fears over AI disruption, creating buying opportunities for high-quality businesses [1] Group 1: Company Overview - Doximity, a social feed and software provider for doctors, has seen its stock fall by 66% in the past year, trading close to an all-time low [2] - The company has a market cap of $4.7 billion, with a current stock price of $25.57 and a 52-week range of $23.66 to $76.51 [3] - Doximity began as a social network for medical professionals, allowing them to receive healthcare news and collaborate in a HIPAA-compliant manner [3] Group 2: Business Model - Doximity generates revenue through sponsorships from pharmaceutical companies, with 126 customers spending over $500,000 annually on the platform [4] - Approximately 85% of physicians in the U.S. use Doximity, indicating a strong market presence with little competition [4] Group 3: Growth Potential - The company is expanding into new software tools, including the DoxGPT AI assistant, which is expected to increase user engagement and revenue over time [5] - Revenue growth has been significant, increasing by 448% since March 2020, although it has slowed to 10% year-over-year growth last quarter [7] - Doximity has a strong EBIT margin of 38.5%, indicating best-in-class profitability for a software provider [8] Group 4: Investment Consideration - With a price-to-earnings ratio of 21, Doximity may present a growth stock opportunity amidst the current software market dip driven by AI fears [8]

Core Viewpoint - Piper Sandler has raised its price target on Doximity Inc. to $42 from $40 while maintaining an Overweight rating, indicating a positive outlook on the company's stock performance [1] Group 1: Doximity's AI Tool Suite - Insights from a demonstration led by CEO Jeff Tangney highlighted the strengths of Doximity's AI tool suite, particularly DoxGPT, which is noted for its integration within the Doximity ecosystem, the quality and accuracy of clinical reference responses, and a strong evidence base supporting its medical AI capabilities [2] - A new feature called PeerCheck allows healthcare professionals to efficiently transition from clinical questions to citations and original sources, enhancing the utility of DoxGPT [2] Group 2: Market Potential and Stock Valuation - As AI tools like Scribe and DoxGPT become integrated into Doximity's workflow platform, there is an expectation of increased adoption among individual healthcare professionals and enterprise contracts with hospitals and health systems, creating a virtuous cycle [3] - Piper Sandler believes the market is undervaluing DoxGPT's potential, especially following the fiscal third-quarter 2026 EPS results, leading to an updated price target of $42 based on a 20.0x multiple applied to slightly higher calendar 2027 adjusted EBITDA estimates [4]

Unity Software - Unity Software, founded in 2004 and based in San Francisco, provides a software platform for creating and expanding video games across various platforms, including mobile, PC, console, and XR [3] - The company has a market capitalization of approximately $8 billion and has seen its stock decline by 58% year to date [8] - Unity's revenue outlook for Q1 2026 is projected to be between $480 million and $490 million, which is below the Wall Street expectation of $494 million [9] - In Q4 2025, Unity reported a revenue of $503 million, a 10% year-over-year increase, and exceeded forecasts by $10.18 million [10] - Analyst Martin Yang from Oppenheimer maintains a positive outlook on Unity, suggesting that the recent stock sell-off is misplaced and that the company will see accelerating revenue growth and margin expansion in 2026 [11] - The consensus rating for Unity is Moderate Buy, with 15 Buy, 4 Hold, and 1 Sell ratings, and an average target price of $37.53 indicating a potential upside of 102% [12] Thomson Reuters - Thomson Reuters, formed in 2008, is a global information and content conglomerate with a market cap of nearly $37 billion, providing services to professionals in legal, tax, accounting, and compliance fields [13] - The company reported $2 billion in revenue for Q4 2025, a nearly 5% year-over-year increase, and exceeded estimates by $9.5 million [16] - Analyst Drew McReynolds from RBC views the current stock price as an opportunity for investors, projecting a 12-month price target of $126, which implies a 47% gain [17] - The consensus rating for Thomson Reuters is Strong Buy, with 10 Buy and 3 Hold ratings, and an average target price of $134.59 indicating a potential gain of 57% [17] Doximity - Doximity is a health-tech platform designed for medical professionals, connecting approximately 80% of US doctors and 50% of nurse practitioners [20] - The company reported $185.1 million in revenue for fiscal Q3 2026, a 10% year-over-year increase, and exceeded forecasts by $3.5 million [23] - Doximity's shares have declined by 42.5% this year, primarily due to low guidance for fiscal Q4 2026, projecting revenue between $143 million and $144 million compared to a consensus of $150.53 million [22] - Analyst Richard Close from Canaccord believes the recent sell-off is an overreaction and maintains a Buy rating with a price target of $34, predicting a 34% upside [24] - The consensus rating for Doximity is Strong Buy, with 14 Buy and 4 Hold ratings, and an average target price of $41.47 indicating a potential upside of 63% [24]

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that humanoid robots could create a market worth $250 trillion by 2040, representing a major shift in the global economy driven by AI innovation [2] - Major firms like PwC and McKinsey acknowledge the multi-trillion-dollar potential of AI, suggesting a broad consensus on its economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, with its technology posing a threat to competitors [4] - Prominent investors, including Bill Gates and Warren Buffett, recognize AI as a significant technological advancement with the potential for substantial social benefits [8] Market Trends - The AI ecosystem is expected to reshape business operations, government functions, and consumer behavior globally, indicating a paradigm shift in various sectors [2] - The enthusiasm for AI is reflected in the investments and partnerships formed by major tech companies, highlighting the competitive landscape [6

Core Insights - The analyst previously held a hold rating for Doximity Inc. (DOCS) due to high valuation and poor guidance, but the current assessment of the core business suggests potential for improvement [1] Company Analysis - The investment approach emphasizes understanding core economics, including competitive moat, unit economics, reinvestment runway, and management quality, which are crucial for long-term free cash flow generation and shareholder value creation [1] - The focus is on sectors with strong secular tailwinds, indicating a preference for industries that are expected to grow over time [1] Investment Philosophy - The analyst is a self-educated investor with 10 years of experience, currently managing personal funds sourced from friends and family [1] - The motivation for sharing insights on Seeking Alpha is to provide valuable analysis and receive feedback from other investors, aiming to highlight what drives long-term equity value [1]

Core Insights - William Blair Investment Management reduced its position in Doximity by 372,184 shares, valued at approximately $20.89 million, during Q4 2025, resulting in a decrease of $184.77 million in the quarter-end value of its Doximity stake [1][2] Company Overview - Doximity operates a cloud-based digital platform that connects U.S. medical professionals, serving healthcare and pharmaceutical clients [5] - As of February 6, 2026, Doximity's stock price was $27.73, with a market capitalization of $5.09 billion, revenue of $637.78 million, and net income of $239.40 million [4] Stock Performance - Doximity shares have declined by 66% year-over-year, significantly underperforming the S&P 500 by 82 percentage points [3] - The stock is currently trading at 17 times free cash flow, marking its lowest-ever valuation [8] Revenue and Growth - Doximity generates revenue primarily from pharmaceutical manufacturers and healthcare systems, targeting physicians and medical organizations [7] - Sales growth has slowed from 23% in Q3 of the previous year to 10% this year, with management guiding for only 4% growth in Q4 [9]